Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study.

CONCLUSIONS: It has been demonstrated that in real clinical practice, the cost per patient and year for treatment of paediatric spasticity was lower when abobotulinumtoxinA was used. PMID: 27570991 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/27570991?dopt=Abstract

Source: Farmacia Hospitalaria - August 31, 2016 Category: Drugs & Pharmacology Authors: Tapias G, García-Romero M, Crespo C, Cuesta M, Forné C, Pascual-Pascual SI Tags: Farm Hosp Source Type: research